196 related articles for article (PubMed ID: 23398405)
1. The therapeutic potential of immune cross-talk in leishmaniasis.
Hartley MA; Kohl K; Ronet C; Fasel N
Clin Microbiol Infect; 2013 Feb; 19(2):119-30. PubMed ID: 23398405
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulation by chemotherapeutic agents against Leishmaniasis.
Saha P; Mukhopadhyay D; Chatterjee M
Int Immunopharmacol; 2011 Nov; 11(11):1668-79. PubMed ID: 21875692
[TBL] [Abstract][Full Text] [Related]
3. Cross-immunity experiments between different species or strains of Leishmania in rhesus macaques (Macaca mulatta).
Porrozzi R; Teva A; Amaral VF; Santos da Costa MV; Grimaldi G
Am J Trop Med Hyg; 2004 Sep; 71(3):297-305. PubMed ID: 15381810
[TBL] [Abstract][Full Text] [Related]
4. Immunological characteristics of experimental murine infection with Leishmania (Leishmania) amazonensis.
Pereira BA; Alves CR
Vet Parasitol; 2008 Dec; 158(4):239-55. PubMed ID: 18922635
[TBL] [Abstract][Full Text] [Related]
5. Protease inhibitors in potential drug development for Leishmaniasis.
Das P; Alam MN; Paik D; Karmakar K; De T; Chakraborti T
Indian J Biochem Biophys; 2013 Oct; 50(5):363-76. PubMed ID: 24772958
[TBL] [Abstract][Full Text] [Related]
6. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
[TBL] [Abstract][Full Text] [Related]
7. Leishmania RNA virus: when the host pays the toll.
Hartley MA; Ronet C; Zangger H; Beverley SM; Fasel N
Front Cell Infect Microbiol; 2012; 2():99. PubMed ID: 22919688
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of Trypanosoma cruzi and Leishmania interaction with their host(s): exploitation of immune and defense mechanisms by the parasite leading to persistence and chronicity, features reminiscent of immune system evasion strategies in cancer diseases.
Ouaissi A; Ouaissi M
Arch Immunol Ther Exp (Warsz); 2005; 53(2):102-14. PubMed ID: 15928579
[TBL] [Abstract][Full Text] [Related]
9. Leishmaniases and HIV/AIDS co-infections: review of common features and management experiences.
Ali A
Ethiop Med J; 2002 Apr; 40 Suppl 1():37-49. PubMed ID: 12802830
[TBL] [Abstract][Full Text] [Related]
10. Antimicrobial peptides for leishmaniasis.
Cobb SL; Denny PW
Curr Opin Investig Drugs; 2010 Aug; 11(8):868-75. PubMed ID: 20721829
[TBL] [Abstract][Full Text] [Related]
11. Detection of Leishmania RNA virus in Leishmania parasites.
Zangger H; Ronet C; Desponds C; Kuhlmann FM; Robinson J; Hartley MA; Prevel F; Castiglioni P; Pratlong F; Bastien P; Müller N; Parmentier L; Saravia NG; Beverley SM; Fasel N
PLoS Negl Trop Dis; 2013; 7(1):e2006. PubMed ID: 23326619
[TBL] [Abstract][Full Text] [Related]
12. Serodiagnosis of leishmaniasis.
Kar K
Crit Rev Microbiol; 1995; 21(2):123-52. PubMed ID: 7639932
[TBL] [Abstract][Full Text] [Related]
13. The immunology of Leishmania infection and the implications for vaccine development.
Vanloubbeeck Y; Jones DE
Ann N Y Acad Sci; 2004 Oct; 1026():267-72. PubMed ID: 15604504
[TBL] [Abstract][Full Text] [Related]
14. Leishmania major: activity of tamoxifen against experimental cutaneous leishmaniasis.
Eissa MM; Amer EI; El Sawy SM
Exp Parasitol; 2011 Aug; 128(4):382-90. PubMed ID: 21620834
[TBL] [Abstract][Full Text] [Related]
15. [Immunopathology of American tegumentary leishmaniasis].
Castés M; Tapia FJ
Acta Cient Venez; 1998; 49(1):42-56. PubMed ID: 10205916
[TBL] [Abstract][Full Text] [Related]
16. [Immunopathogenesis of Leishmania infections].
Yurdakul P
Mikrobiyol Bul; 2005 Jul; 39(3):363-81. PubMed ID: 16358498
[TBL] [Abstract][Full Text] [Related]
17. Uptake and antileishmanial activity of meglumine antimoniate-containing liposomes in Leishmania (Leishmania) major-infected macrophages.
Borborema SE; Schwendener RA; Osso JA; de Andrade HF; do Nascimento N
Int J Antimicrob Agents; 2011 Oct; 38(4):341-7. PubMed ID: 21783345
[TBL] [Abstract][Full Text] [Related]
18. Leishmaniasis and various immunotherapeutic approaches.
Taslimi Y; Zahedifard F; Rafati S
Parasitology; 2018 Apr; 145(4):497-507. PubMed ID: 27974063
[TBL] [Abstract][Full Text] [Related]
19. The enemy within: Targeting host-parasite interaction for antileishmanial drug discovery.
Lamotte S; Späth GF; Rachidi N; Prina E
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005480. PubMed ID: 28594938
[TBL] [Abstract][Full Text] [Related]
20. Improvement of the green fluorescent protein reporter system in Leishmania spp. for the in vitro and in vivo screening of antileishmanial drugs.
Pulido SA; Muñoz DL; Restrepo AM; Mesa CV; Alzate JF; Vélez ID; Robledo SM
Acta Trop; 2012 Apr; 122(1):36-45. PubMed ID: 22155571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
